- Title
- Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF)
- Creators - without role
- Loïc Lebellec - Centre Oscar LambretBruno Chauffert - Centre Hospitalier Universitaire Amiens-PicardieJean-Yves Blay - Centre de Recherche en Cancérologie de LyonAxel Le Cesne - Institut Gustave RoussyChristine Chevreau - Institut Claudius RegaudEmmanuelle Bompas - Centre Hospitalier René-DubosFrançois Bertucci - Institut Paoli-CalmettesDidier Cupissol - Université de Montpellier, Institut de Recherche en Cancérologie de Montpellier - IRCMMichel Fabbro - Institut de Recherche en Cancérologie de MontpellierEsma Saada Saada-Bouzid - Centre Antoine LacassagneFlorence Duffaud - Medical Oncology UnitLoic Feuvret - Sorbonne UniversitéAlice Bonneville-Levard - Centre Léon BérardJacques Olivier Bay - Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemiasElodie Vauleon - Centre Eugène MarquisArmelle Vinceneux - Centre Hospitalier Universitaire de ToursGeorges Noel - Centre Paul StraussNicolas Penel - Centre Oscar LambretOlivier Mir - Institut Gustave Roussy
- Publication Details
- European Journal of Cancer, Vol.79, pp.119 - 128
- Identifiers
- 9938120209311
- Academic Unit
- Institut de Recherche en Cancérologie de Montpellier - IRCM
- Language
- English
- Resource Type
- Journal article
- Local Fields
- hal-01655981
Journal article
Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF)
European Journal of Cancer, Vol.79, pp.119 - 128
07/2017
Metrics
1 Record Views